You are here

  • Home
  • Archive
  • Volume 109, Issue 2
  • Do proton pump inhibitors reduce gastrointestinal complication when starting long-term non-steroidal anti-inflammatory drugs therapy?

Article Text

Article menu
Download PDFPDF
Archimedes
Do proton pump inhibitors reduce gastrointestinal complication when starting long-term non-steroidal anti-inflammatory drugs therapy?
  1. Simona Riccio1,
  2. Pierluigi Marzuillo1,
  3. Claudia Santoro1,2
  1. 1 Department of Women’s and Children’s Health and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy
  2. 2 Clinic of Child and Adolescent Neuropsychiatry, Departments of Physical and Mental Health, and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
  1. Correspondence to Dr Claudia Santoro, Department of Women’s and Children’s Health and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy; dr.claudiasantoro{at}gmail.com

https://doi.org/10.1136/archdischild-2023-326141

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Clinical scenario

    A 9-year-old child with a diagnosis of juvenile idiopathic arthritis needs to start a non-steroidal anti-inflammatory drug (NSAID) therapy. You are aware of gastrointestinal (GI) adverse effects of NSAIDs and you wonder if it might be worth adding a proton pump inhibitor (PPI).

    Structured clinical question

    Should children starting long-term NSAID therapy (patients) receive PPI prophylaxis (intervention) to prevent GI adverse events (AEs) (outcome)?

    Search strategy

    PubMed was searched (2003–2023) using the following terms (‘child’ OR ‘children’ OR ‘paediatric’) AND ‘non-steroidal anti-inflammatory drug’ AND (‘gastric bleeding’ OR ‘duodenal bleeding’ OR ‘gastrointestinal perforation’ OR ‘peptic ulcer’) AND ‘gastropathy prophylaxis’ AND ‘proton pump inhibitor’. Meta-analysis, randomised clinical trial (RCT) and systematic review with the filters ‘English’ and ‘child’ were included. No study was eligible among the eight records that were screened and neither were any clinical trials ongoing (clinical trial.gov on 16 August 2023). Given this, we conducted similar research on adults using: ‘non-steroidal anti-inflammatory drug’ AND ‘(prevention OR prophylaxis)’ AND ‘(gastroduodenal ulcers OR peptic ulcer OR …

    View Full Text

    Footnotes

    • Contributors SR, PM and CS contributed equally to the planning, conduct and reporting of the work described in the article.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.